Rochester, N.Y.-based ACM Global Central Laboratory expanded its global reach with the acquisition of York, UK-based Pivotal Laboratories, a central lab serving Europe, Israel and South Africa. Neither company provided details about the terms of the acquisition agreement. ACM and Pivotal had a long-time exclusive partnership before this deal.

The Pivotal acquisition will enable ACM to further standardize and streamline its operations, according to an ACM release. Pivotal’s specific emphasis is on growing within the countries of Central and Eastern Europe.

“Our success and growth in the global market made this an economically viable business decision, and this was the next logical step in our relationship,” said Art Glenz, president and CEO of ACM Medical Laboratory, in a company release. “The complete integration of the two companies places us in a stronger position, as we anticipate continued growth in the global clinical trials market.”

The acquisition will increase ACM’s employee base in both the U.S. and the UK, according to the release.